In a year marked by shifts in the pharmaceutical landscape, Humana Inc. (NYSE:HUM) stands out as a strategic player amid a bustling industry scenario. While 2024 saw a steady stream of smaller, more tactical mergers, the overarching pharmaceutical sector is gearing up

In recent developments, Acelyrin Inc. faces a mixed bag of news as it navigates clinical and financial territories. The company’s clinical trial for its drug, izokibep, aimed at treating uveitis, did not meet its primary goal. When compared with a placebo, both

SpaceX Surges Ahead in Satellite Communications SpaceX has significantly enhanced its position in the direct-to-cell (DTC) communication market, challenging smaller competitors like AST SpaceMobile. Earlier predictions underestimated SpaceX’s swift progress in deploying Starlink satellites capable of facilitating direct calls between regular cell